A nucleic acid extraction-free inactivated virus preservation solution and its application

By using a virus preservation solution containing components such as proteinase K, sodium hydroxide, β-propiolactone, and gelatin, room temperature inactivation of the virus and stable preservation of nucleic acid were achieved. This solved the problems of difficulty in inactivating the virus at room temperature and the need for nucleic acid extraction, simplifying the virus detection process and improving safety and detection efficiency.

CN112725406BActive Publication Date: 2024-11-01JIANGSU COWIN BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110034972.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-01-12
Publication Date
2024-11-01
Estimated Expiration
2041-01-12

AI Technical Summary

Technical Problem

Existing virus preservation solutions are difficult to effectively inactivate viruses at room temperature and require nucleic acid extraction, which poses safety risks and is cumbersome to operate.

Method used

A virus preservation solution containing proteinase K, sodium hydroxide, β-propiolactone, gelatin, and other components can inactivate the virus and release nucleic acid at room temperature, simplifying it into a virus preservation solution that does not require nucleic acid extraction and can be directly used for PCR amplification and detection.

Benefits of technology

This method enables room-temperature inactivation of the virus and stable preservation of nucleic acid, simplifies the operation process, reduces the time and cost of nucleic acid testing, and improves safety and detection sensitivity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112725406B_ABST
    Figure CN112725406B_ABST
Patent Text Reader

Abstract

The present invention provides an inactivated virus preservation solution free of nucleic acid extraction and an application thereof. Specifically, the virus sample preservation solution of the present invention comprises components such as proteinase K, sodium hydroxide, β-propiolactone, gelatin, etc., and can effectively release and preserve viral nucleic acids under room temperature conditions through the coordinated cooperation of the components, and effectively prevent nucleic acid degradation during sample transportation and storage at room temperature, and can be used for preparing clinical viral nucleic acid samples.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of molecular diagnosis, and in particular relates to an inactivated virus preservation solution free of nucleic acid extraction and application thereof. Background Art

[0002] The nucleic acid of RNA viruses is one of the most difficult biological molecules to preserve stably due to self-degradation and degradation caused by biological enzymes. Therefore, the preservation and transportation of samples are usually key factors in determining the quality of RNA virus samples. Samples containing RNA viruses are recommended to be stored in a special virus preservation solution and must be stored in a refrigerated state (i.e. 4°C or lower) and transported for inspection as soon as possible. In the clinical detection of highly infectious pathogen nucleic acids, clinical inspectors are prone to the threat of laboratory exposure to infectious pathogens during the inspection operation, and strict protective equipment and measures need to be taken to reduce the risk of infection for clinical inspectors. Therefore, how to effectively preserve and transport pathogen samples on the basis of protecting the safety of clinical inspectors and ensure the accuracy of subsequent nucleic acid test results has put forward higher requirements for the collection and preservation of pathogen nucleic acid samples in clinical practice.

[0003] In addition, since virus preservation is mainly about solving problems in sample preservation and transportation, subsequent testing is based on the isolation and extraction of viral nucleic acid. Before implementing PCR and other nucleic acid tests, samples need to go through multiple steps such as sample digestion and lysis, adsorption purification, washing and collection to remove protein denaturants, detergents and other lysis reagents in the samples. The processing of a single sample often takes tens of minutes. When a large number of samples need to be processed, it takes even longer than the PCR test reaction. In addition, due to the numerous operating steps, the chance of cross-contamination between samples is also increased during the large sample processing process.

[0004] In response to the problems of sample nucleic acid preservation, virus inactivation, and subsequent direct amplification involved in the above virus preservation process, the patent CN111334503A "A Nucleic Acid Preservation Solution" developed by this laboratory provides an inactivated virus preservation solution that can inactivate pathogenic microorganisms and effectively prevent the degradation of nucleic acids at room temperature, prolong the storage time of nucleic acids, and ensure the safety and stability of virus sample collection, transportation, and detection, effectively solving the problems of virus inactivation and nucleic acid transportation and storage at room temperature. However, samples preserved in the preservation solution still need to go through the nucleic acid extraction step and are not suitable for direct RT-PCR amplification detection. Another patent CN111925941A "A Virus Preservation Solution and Its Application" developed by this laboratory discloses a virus preservation solution that does not require nucleic acid extraction, which can effectively prevent viral nucleic acids from being degraded during transportation and storage at room temperature and high-temperature virus inactivation treatment. The preservation solution does not contain PCR inhibitors, and can be used directly as a sample template for subsequent (RT-)PCR nucleic acid detection experiments without nucleic acid extraction. However, the preservation solution cannot completely and effectively inactivate pathogenic microorganisms such as viruses. Therefore, before nucleic acid testing, the samples need to be inactivated at high temperature (50-60°C) to ensure the safety of experimental operators.

[0005] Therefore, those skilled in the art are committed to developing a virus preservation solution that can effectively inactivate viruses and avoid nucleic acid extraction. Summary of the invention

[0006] The purpose of the present invention is to provide an inactivated virus preservation solution free of nucleic acid extraction and application thereof.

[0007] In a first aspect of the present invention, a virus sample preservation solution is provided, the preservation solution comprising a protein denaturant, an inactivator, and a stabilizer; wherein:

[0008] The protein denaturant comprises one or two components selected from the group consisting of proteinase K and sodium hydroxide;

[0009] The inactivator comprises one or two components selected from the group consisting of β-propiolactone and Procl in-300;

[0010] The stabilizer comprises one or two components selected from the group consisting of gelatin and PEG8000.

[0011] In another preferred embodiment, the preservation solution further comprises a non-ionic surfactant; preferably, the non-ionic surfactant comprises one or more components selected from the following group: Triton-100, Tween 20, Tween 80, and NP-40.

[0012] In another preferred embodiment, the preservation solution also includes a zwitterionic buffer; preferably, the zwitterionic buffer is an organic buffer solution and / or an inorganic buffer solution; more preferably, the organic solution can be Tris, ethanolamine, triethanolamine, glycine, glycine, mannose or trisodium citrate, etc., and the inorganic solution can be carbonate, bicarbonate, phosphate or borate.

[0013] In another preferred embodiment, the preservation solution also includes a chelating agent; preferably, the chelating agent includes one or more components selected from the following group: ethylenediaminetetraacetic acid (EDTA), citric acid, ethylene glycol diethyl ether diaminetetraacetic acid (EGTA) and nitrilotriacetic acid trisodium salt monohydrate (NTA).

[0014] In another preferred embodiment, the preservation solution comprises: NaOH, proteinase K, β-propiolactone and gelatin.

[0015] In another preferred embodiment, the preservation solution further comprises one or more components selected from the following group: Tris-HCl, EDTA, Triton-100, and Proclin-300.

[0016] In another preferred embodiment, the storage solution contains 10-200 mM NaOH.

[0017] In another preferred embodiment, the storage solution contains 10-30 mg / L of proteinase K.

[0018] In another preferred embodiment, the storage solution contains 10-200 mM Tris-HCl.

[0019] In another preferred embodiment, the storage solution contains 0.5-10 mM EDTA.

[0020] In another preferred embodiment, the storage solution contains Triton-100 0.01-1% (v / v).

[0021] In another preferred embodiment, the preservation solution contains Proclin-300 0.01-0.05% (w / v).

[0022] In another preferred embodiment, the preservation solution contains 0.001-0.005% (w / v) β-propiolactone.

[0023] In another preferred embodiment, the preservation solution contains 1-5% (w / v) gelatin.

[0024] In another preferred embodiment, the pH value of the preservation solution is 7-9.

[0025] A second aspect of the present invention provides a kit, wherein the kit comprises the virus sample preservation solution described in the first aspect of the present invention.

[0026] In another preferred example, the kit further comprises a PCR detection reagent.

[0027] The third aspect of the present invention provides a method for preparing a viral nucleic acid sample, the method comprising the steps of:

[0028] The biological sample is fully contacted with the virus sample preservation solution described in the first aspect of the present invention to prepare the virus nucleic acid sample.

[0029] In another preferred embodiment, the biological sample includes: a swab sample, a sputum sample, a saliva sample, a bronchoalveolar lavage fluid, a blood sample, a urine sample, etc.

[0030] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 .Statistics of chicken embryo development after inoculation with inactivated virus preservation solution.

[0032] Figure 2 .Direct amplification effect detection of virus preservation solution. DETAILED DESCRIPTION

[0033] The inventors have obtained a virus sample preservation solution through extensive and in-depth research. The present invention preferably contains components such as proteinase K, sodium hydroxide, β-propiolactone, gelatin, etc. in the virus sample preservation solution. Through the coordinated cooperation of each component, the virus nucleic acid can be effectively released and preserved under room temperature conditions, and the nucleic acid degradation can be effectively prevented during the transportation and storage of the sample at room temperature, and can be used to prepare clinical virus nucleic acid samples. In particular, the inventors unexpectedly discovered during the research process that adding gelatin components to the virus sample preservation solution can not only ensure the virus inactivation effect of clinical samples, but also significantly reduce the influence of chemical components in the sample preservation solution on subsequent PCR amplification, so that the nucleic acid extraction step can be avoided, and it can be directly added to the (RT-)PCR amplification reagent system for gene amplification detection, which greatly simplifies the virus detection operation process and time.

[0034] The kit and the matching method of the present invention have high sensitivity, short time consumption and strong applicability.

[0035] Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can be changed. It should also be understood that the terminology used herein is intended only to describe specific embodiments, and is not intended to be restrictive, and the scope of the present invention will be limited only by the appended claims.

[0036] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. As used herein, the term "about" when used in reference to a specific recited value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes 99 and 101 and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0037] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.

[0038] The purpose of the present invention is to provide an inactivated and direct amplification virus preservation solution, and apply it to viral nucleic acid PCR direct amplification detection, inactivate pathogens, prevent pathogen spread, simplify operation steps, and shorten viral nucleic acid detection time and cost.

[0039] In order to achieve the above purpose, the present invention provides an inactivated and direct-expansion virus preservation solution, comprising the following components: a denaturant, a zwitterionic buffer, a nonionic surfactant, a chelating agent, an antibacterial / inactivating agent, a solubilizer / emulsifier, and a pH of 7.0-9.0.

[0040] The denaturant includes one or both of proteinase K and sodium hydroxide. Proteinase K can directly cleave the virus to release nucleic acid and eliminate nuclease (RNase / DNase) to prevent viral nucleic acid degradation. In addition, proteinase K can be used as an inactivator to denature the viral coat protein, so that the virus loses its activity and "dies", is no longer infectious, and improves the safety of the transportation and detection stages.

[0041] The nonionic surfactant can be one or more of Tween 20, Tween 80, NP-40 and Triton-100, which can gently destroy cells or viruses to release nucleic acids. The present invention preferably uses 0.01-1% Triton-100. Triton X-100 is a relatively mild nonionic surfactant that can dissolve lipids, destroy cells, destroy the connection between proteins-lipids and lipids-lipids, dissolve and separate proteins, but retain the natural conformation, function and interaction of proteins.

[0042] The chelating agent is one or more of ethylenediaminetetraacetic acid (EDTA), citric acid, ethylene glycol diethyl ether diaminetetraacetic acid (EGTA) and nitrilotriacetic acid trisodium salt monohydrate (NTA), preferably 0.5-5mM EDTA. EDTA is a commonly used Mg 2+ , Ca 2+ , Mn 2+ , Fe 2+ Divalent metal ion chelators such as Mg- 2+ It can inhibit the activity of nucleases, reduce the risk of nuclease degradation of nucleic acids, and help maintain the stability of nucleic acids. In addition, EDTA also has the function of a denaturant.

[0043] The zwitterionic buffer may be an organic buffer solution and / or an inorganic buffer solution, wherein the organic solution may be Tris, ethanolamine, triethanolamine, glycine, glycine, mannose or trisodium citrate, etc., and the inorganic solution may be carbonate, bicarbonate, phosphate or borate. The present invention preferably uses Tris-HCl with a final concentration of 10mM-200mM, which can provide a sufficient buffer environment, maintain the stability of the preservation solution, and maintain the stability of the nucleic acid to avoid the occurrence of deamination.

[0044] The stabilizer includes one or both of gelatin and PEG8000. In the present invention, gelatin with a final concentration of 1-5% is preferred.

[0045] The inactivating (bacteriostatic) agent includes one or both of Procl in-300 and β-propiolactone. β-propiolactone (BPL) is used as a vaccine inactivator, which can directly act on nucleic acids and has a strong inactivation ability for viruses. ProClin biological inactivator has a broad spectrum of antibacterial properties, fast action speed, low dosage, can quickly penetrate the cell membrane, and inhibit specific enzymes that are essential for cell respiration. Therefore, once it contacts microbial organisms, it will immediately inhibit cell activity. 6-20ppm of ProClin300 can achieve the purpose of antibacterial, and its toxicity is much lower than that of similar products such as thimerosal, and it has good compatibility with enzymes and diagnostic factors, and will not affect related reactions with enzymes or antibodies.

[0046] In some embodiments, the virus preservation solution may include the following ingredients (in the total amount of the solution): 10-100 mM NaOH, 10-20 mg / L proteinase K, 10-100 mM Tris-HCl, 1-10 mM EDTA, 0.01-1% volume fraction of Triton-100, 0.01-0.05% Procl in-300, 0.001-0.005% β-propiolactone and 1-5% gelatin, and the preservation solution has a pH value of 7-9. In some embodiments, the virus preservation solution may further include 1-10 mg / ml BSA. The main components of the cell membrane are phospholipids, and the virus shell is composed of proteins or lipoproteins. Under the dual action of NaOH and proteinase K, the alkaline environment provided by them causes ester bonds to break, cells to lyse, and proteins to denature. Triton-100, as a mild non-ionic detergent, replaces ionic denaturants such as SDS to gently lyse cells, dissociate proteins, and release viral nucleic acids. Tris-HCl buffer maintains the pH buffer environment and keeps the released nucleic acids stable. EDTA chelates divalent metal ions in the sample and acts as an RNase inhibitor to protect viral RNA nucleic acids from degradation. Proclin-300 and β-propiolactone, as antibacterial agents and inactivators, can effectively inactivate pathogen activity and prevent pathogen spread. BSA is an enzyme stabilizer, which can reduce the decomposition and denaturation of enzymes caused by adverse environmental factors such as heating, surface tension and chemical factors in subsequent nucleic acid direct amplification detection, and can prevent the enzyme from being lost by non-specific adsorption to the tube wall. Gelatin, as a stabilizer, can increase the stability of the preservation solution. The sample preservation solution can be directly used as a template for PCR nucleic acid detection without the need for nucleic acid extraction operations, and is compatible with most PCR amplification reagents.

[0047] In another preferred embodiment of the present invention, the present invention provides a method for collecting and preserving virus samples and performing PCR detection, wherein the collected virus nasopharyngeal swab samples are preserved using the virus preservation solution provided by the present invention, and no nucleic acid extraction step is required. An appropriate amount of sample preservation solution is taken directly as a template for PCR nucleic acid detection. The specific steps are:

[0048] 1) Collect virus swabs;

[0049] 2) Add 0.5-1 mL of virus preservation solution and place at room temperature (18-26°C) for 5 minutes to inactivate the virus and release the nucleic acid;

[0050] 3) Take out 10-25 μL (the template addition amount does not exceed 50% of the total PCR system) as a template and add it to the (RT-)PCR system (20-50 μL) for viral nucleic acid detection.

[0051] In summary, the present invention provides an extraction-free virus inactivation preservation solution, which can effectively inactivate viruses, realize the storage and transportation of samples at room temperature, and can be directly added to the PCR amplification reagent system for pathogen gene nucleic acid amplification detection without the extraction step.

[0052] The main advantages of the present invention are:

[0053] (1) Storage and transportation at room temperature: The virus preservation solution provided by the present invention has simple ingredients and low cost. It can effectively release and preserve viral nucleic acids under room temperature conditions and effectively prevent nucleic acid degradation during sample transportation and storage at room temperature. It can keep virus samples at 15-37°C for at least 7 days, reducing the possibility of nucleic acid degradation due to improper transportation or storage, and solving the problem that traditional virus preservation solutions have a short preservation time for samples and require low-temperature storage.

[0054] (2) Inactivation of viruses: The virus preservation solution provided by the present invention is an inactivated virus preservation solution that can quickly inactivate viruses and make them no longer active. It is very safe for operators and the environment, and does not require a high-temperature inactivation treatment step. It can avoid the degradation of viral RNA / DNA nucleic acids caused by the high-temperature inactivation process and reduce the missed detection rate.

[0055] (3) No nucleic acid extraction required: The virus preservation solution provided by the present invention adopts a simple formula component and is compatible with common PCR amplification reagents on the market. It does not require a nucleic acid extraction step and can be directly added to the (RT-)PCR amplification reagent system for gene amplification detection, greatly simplifying the virus detection operation process and time.

[0056] The present invention will be further described in detail below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where detailed conditions are not specified are usually carried out according to conventional conditions such as the conditions described in "Molecular Cloning Laboratory Guide" by Sambrook.J et al. (Huang Peitang et al., Beijing: Science Press, 2002), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight. The experimental materials and reagents used in the following examples can be obtained from commercial channels unless otherwise specified.

[0057] Example 1. Virus sample preservation solution formula

[0058] The formula of the non-extraction virus sample preservation solution of the present invention mainly comprises the following components: NaOH, proteinase K, Tris-HCl, Triton-100, EDTA, gelatin, Proclin-300 and beta-propiolactone. wherein the final concentration of Tris HCl is 10-200mM, preferably 50-100mM; the final concentration of Triton-100 is 0.01-1% (v / v), preferably 0.01-0.5%; the final concentration of EDTA is 0.5-5mM, preferably 0.5-1mM; the final concentration of gelatin is 1-5%, preferably 2-4%; the final concentration of NaOH is 10-200mM, preferably 50-100mM; the final concentration of proteinase K is 10-30mg / L, preferably 10-20mg / L; the final concentration of Proclin-300 is 0.01-0.5%, preferably 0.01-0.05%; the final concentration of β-propiolactone is 0.001-0.05%, preferably 0.001-0.005%; and the pH value of the virus preservation solution is 7-9, preferably 7-8.

[0059] Table 1. Virus storage solution formula

[0060]

[0061] Example 2. Study on the inactivation efficacy of inactivated direct expansion storage fluid on avian infectious bronchitis virus

[0062] Experimental group preservation solution: Virus preservation solution No. 1, 2, 3, 4 in Example 1

[0063] Control group preservation solution: inactivated virus preservation solution invented by patent CN111334503A (including 5mg / ml nuclease inhibitor EDTA, 40mg / ml protein denaturant SDS, 50mg / ml stabilizer glycine, 100mg / ml antibacterial agent potassium sorbate, 80mM Tricine salt buffer.)

[0064] Experimental materials: 10-day-old SPF chicken embryos (purchased from Yangzhou), experimental virus strain IBV seed virus (stored in a -80℃ refrigerator).

[0065] Experimental method: The experimental setting is as shown in Table 2. The prepared chicken infectious bronchitis virus IBV strain seed virus of equal portions is added to the virus preservation fluid of the experimental group and the control group respectively, and mixed in the ratio of 1 (virus stock solution): 10 (virus preservation fluid), and the virus is inactivated at room temperature of 18-26 ℃ for 5 min. Then, the virus liquid after the inactivation is inoculated into 10-day-old SPF chicken embryos by the allantoic cavity inoculation mode. Each virus preservation fluid sample is inoculated with 3 chicken embryos, 0.1 mL / piece, and is placed in a 37 ℃ incubator for cultivation after inoculation. The death of chicken embryos is observed and recorded every day, and the chicken embryo pathological changes are observed by dissection after 168 h of inoculation and culture, and the chicken embryo allantoic fluid is harvested for viral nucleic acid PCR detection to determine whether it is infected. The harvested chicken embryo allantoic fluid was tested for infectious bronchitis virus nucleic acid. The detection method referred to GB / T23197-2008 Diagnostic Technology for Infectious Bronchitis in Chickens. RNA was extracted using a viral RNA extraction kit (Kangwei Century, Product No. CW3023), and viral nucleic acid was detected using one-step RT-qPCR (Kangwei Century, Product No. 2207).

[0066] Table 2. Experimental setup for virus inactivation and inoculation into chicken embryos

[0067]

[0068] Experimental results: After the chicken embryos were inoculated with the virus, the development of the chicken embryos was observed and recorded during the culture process. The results are shown in Table 3 and Figure 1 As shown, 3 healthy chicken embryos not inoculated with any virus all developed normally, and no lesions and deaths occurred after 168h of culture; the chicken embryos were inoculated with the preservation solution of the experimental groups 1, 2, 3, and 4 and the preservation solution of the control group after inactivating the virus, and the death of the chicken embryos was counted by taking pictures of the embryos every day. During the observation period, groups 1, 2, 4, and 5 all showed normal growth of chicken embryos, and only one chicken embryo in group 3 died after 120h of inoculation and culture, and the remaining two chicken embryos in group 3 had no abnormal development. After 168h, the autopsy observation found that one case of death in group 3 had no obvious lesions, and the IBV virus nucleic acid test was also negative, so this case of death of chicken embryos was not caused by IBV virus infection; after the virus control group (normal saline mixed virus) of group 6 was inoculated, one of them died after 96h of culture, and the autopsy observation found that all three chicken embryos had lesions, and the IBV virus nucleic acid test was positive after 168h of culture. This shows that the preservation solution of the experimental groups 1, 2, 3, and 4 and the preservation solution of the control group can effectively inactivate the virus.

[0069] Table 3 Statistics of inactivation efficacy of inactivation preservation solution

[0070]

[0071] Figure 1 .Statistics of chicken embryo development after inoculation with inactivated virus preservation solution.

[0072] Example 3. Study on the preservation ability of virus preservation fluid on RNA viruses

[0073] In this embodiment, avian IBV virus (coronavirus, RNA virus, not infectious to humans) was used as a model to detect the preservation effect of the inactivated direct-expansion virus preservation solution provided by the present invention on RNA virus sample nucleic acid under different storage temperature conditions.

[0074] Experimental materials: No. 1, 2, 3, 4 virus storage solutions in Example 1, and IBV virus seed for the experiment (stored in a -80°C refrigerator).

[0075] Experimental method: Add 20 μl of IBV virus stock solution to virus preservation solution No. 1, 2, 3, and 4 respectively, invert and mix, divide each sample into three equal parts, store at 37°C, 4°C, and -80°C respectively, take out on the 7th day, take 10 μl of each sample as a template (the amount of template added does not exceed 50% of the total RT-PCR system) and directly perform RT-qPCR detection.

[0076] The extracted nucleic acid samples were tested by one-step reverse transcription fluorescence quantitative PCR (RT-PCR) using Kangwei Century qPCR detection reagent (CW2207). For specific operations, refer to the instructions. The primer sequence information for PCR detection is IBV-F: GCTTTTGAGCCTAGCGTT, IBV-R: GCCATGTTGTCACTGTCTATTG, and the probe sequence information is IBV-P: CACCACCAGAACCTGTCACCTC. The reaction system uses 15μl PCR reaction solution (including 12.5μl reaction buffer, 0.5μl each of the pre-amplification / post-amplification primers (10μM), 0.5μl of the probe (10μM), and 1μl of the enzyme) + 10μl sample template. IBV nucleic acid detection was performed on an ABI7500 (Thermofisher, USA) fluorescence quantitative PCR instrument, and the reaction conditions were as follows: 50℃15min→94℃10min→94℃15s, 60℃30s (40 cycles), FAM channel. All tests were repeated 3 times, and the average Ct value was calculated.

[0077] Experimental results: The results are shown in Table 4. Compared with the Ct of the control group on day 0, the Ct differences of samples stored in No. 1, 2, and 3 preservation solutions after being stored at -80°C, 4°C, and 37°C for 7 days were basically within 1, and most of the differences were not significant (p>0.05), indicating that the three preservation solutions can effectively protect viral RNA nucleic acids under different temperature conditions and can ensure effective detection of nucleic acids even after 7 days of storage. Samples stored in No. 4 preservation solution were directly tested by RT-qPCR after being stored at -80°C and 4°C for 7 days. The amplification curve was abnormal and it was impossible to determine whether the sample contained IBV targets; after being stored at 37°C for 7 days, RT-qPCR was directly tested, and the IBV targets could not be detected.

[0078] Table 4. RT-qPCR detection of the preservation effect of virus preservation solution on avian IBV virus nucleic acid (RNA virus)

[0079]

[0080]

[0081] After the samples preserved in No. 4 preservation solution were stored at -80℃, 4℃ and 37℃ for 7 days, the RNA extraction kit was used to extract viral RNA nucleic acid (Kangwei Century, catalog number CW3023). The specific extraction operation is detailed in the instructions. Finally, 50μl of nuclease-free water was used to elute the viral nucleic acid, and 10μl was taken as the template for subsequent RT-PCR amplification detection. Then, one-step reverse transcription fluorescence quantitative PCR (RT-PCR) detection was performed according to the above steps.

[0082] The test results are shown in Table 5. The samples preserved in No. 4 preservation solution were stored at -80°C, 4°C, and 37°C for 7 days, and then nucleic acid was extracted and then viral nucleic acid was tested. The Ct values ​​(mean ± standard deviation) were significantly higher than the Ct values ​​at 0 days of storage (p < 0.05).

[0083] Combined with the data analysis in Table 4, it can be seen that if RT-qPCR is directly performed on samples preserved in No. 4 preservation solution, the samples will obviously interfere with subsequent PCR amplification, and the nucleic acid target will be obviously damaged during the preservation process.

[0084] Table 5. PCR virus detection after extraction of samples from No. 4 preservation solution

[0085]

[0086] Example 4. Study on the effect of direct PCR amplification of viral nucleic acid using virus storage solution

[0087] In this example, avian IBV virus (coronavirus, RNA virus, not infectious to humans) was used as a model to detect the effect of the virus preservation solution provided by the present invention on PCR direct amplification of RNA virus sample nucleic acid.

[0088] Experimental group: IBV virus was preserved using the No. 1 virus preservation solution in Example 1 above;

[0089] Control group: IBV virus was preserved using a preferred formula of a virus preservation solution without nucleic acid extraction published in patent CN111925941A (comprising 50 mM Tris-HCl, 0.5% Triton-100, 4 mM DTT, 10 mM TCEP·HCl, 4 μg / μl BSA, 1% DMSO and 2% glycerol).

[0090] The virus storage solution of the experimental group and the control group was used to dilute the avian IBV virus stock solution (20 μl) into 10 -3 ,10 -4 ,10 -5 ,10 -6 Dilution gradient, place the diluted virus preserved sample samples at room temperature (18-26℃) for reaction for 5 minutes, divide each sample into 2 equal parts, one part (200μl) is temporarily placed at 4℃ for standby use, and 10μl is directly taken as a template for RT-qPCR detection in the subsequent direct amplification experiment; the other part (200μl) is used for viral RNA nucleic acid extraction using an RNA extraction kit (Kangwei Century, product number CW3023). For specific extraction operations, please refer to the instructions, and finally use 50μl RNase-Free Water to elute the viral nucleic acid, and take 10μl as a template for subsequent RT-PCR amplification detection.

[0091] The samples directly amplified from the storage solution and the extracted nucleic acid samples were tested by one-step reverse transcription fluorescence quantitative PCR (RT-PCR) using Kangwei Century qPCR detection reagent (CW2207). For specific operations, refer to the instructions. The primer sequence information for PCR detection is IBV-F: GCTTTTGAGCCTAGCGTT, IBV-R: GCCATGTTGTCACTGTCTATTG, and the probe sequence information is IBV-P: CACCACCAGAACCTGTCACCTC. The reaction system uses 15μl PCR reaction solution (including 12.5μl reaction buffer, 0.5μl each of the pre-amplification / post-amplification primers (10μM), 0.5μl of the probe (10μM), and 1μl of enzyme) + 10μl sample template. IBV nucleic acid detection was performed on an ABI7500 (Thermofisher, USA) fluorescence quantitative PCR instrument, and the reaction conditions were as follows: 50℃15min→94℃10min→94℃15s, 60℃30s (40 cycles), FAM channel. All tests were repeated 3 times, and the average CT value was calculated.

[0092] The results are shown in Table 6 and Figure 2 As shown in the figure, the virus preservation fluid of the experimental group and the control group can be directly used as a template for direct amplification detection, and the amplification Ct values ​​of the two groups are comparable, with no significant difference. In addition, compared with the extraction amplification group, the Ct value of the direct amplification group is generally 1-2 Ct values ​​smaller, indicating that the direct amplification group has better detection sensitivity. We speculate that the nucleic acid extraction process will cause partial loss of nucleic acid samples, so the efficiency of viral nucleic acid extraction will also affect the sensitivity of virus detection.

[0093] Table 6. Direct amplification effect of RT-qPCR detection of virus storage solution

[0094]

[0095] Figure 2 .Direct amplification effect detection of virus preservation solution.

[0096] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A virus sample preservation solution, It is characterized in that The preservation solution consists of NaOH 50-100 mM, proteinase K 10-15 mg / L, β-propiolactone 0.001-0.005% (v / v), gelatin 2-4% (w / v), Tris-HCl 50-100 mM, EDTA 0.5-1 mM, Triton-100 0.1-0.5% (v / v), and Proclin-300 0.01-0.05% (v / v).

2. The virus sample preservation solution according to claim 1, It is characterized in that The storage solution contains 80 mM NaOH.

3. The virus sample preservation solution according to claim 1, It is characterized in that The storage solution contains 10 mg / L of proteinase K.

4. The virus sample preservation solution according to claim 1, It is characterized in that The preservation solution contains 0.003% (w / v) β-propiolactone.

5. The virus sample preservation solution according to claim 1, It is characterized in that The preservation solution contains 3% (w / v) gelatin.

6. The virus sample preservation solution according to claim 1, It is characterized in that The storage solution contains 80 mM Tris-HCl.

7. The virus sample preservation solution according to claim 1, It is characterized in that The storage solution contains 0.8 mM EDTA.

8. The virus sample preservation solution according to claim 1, It is characterized in that The storage solution contains Triton-100 0.3% (v / v).

9. The virus sample preservation solution according to claim 1, It is characterized in that The preservation solution contains Proclin-3000.02% (w / v).

10. A kit, It is characterized in that The kit comprises the virus sample preservation solution according to claim 1.

11. A method for preparing a viral nucleic acid sample, It is characterized in that The method comprises the steps of: The biological sample is fully contacted with the virus sample preservation solution according to claim 1 to prepare the virus nucleic acid sample.